Table 3.

Review of the current literature on PD-L1 expression and associated outcomes in patients with UTUC

First author and year	Patient number	Clone	Cutoff for PD-L1 ( +)	Tissue analysis	Impact on pathological feature	Impact on prognosis
Skala, 2017 [23]	149	5H1	≥ 5% of TCs	Whole-tissue sections	Higher grade, T stage and LVI	Worse CSS at TPS ≥ 50%
Krabbe, 2017 [22]	423	E1L3N	≥ 1% of TCs	TMA	Lower T stage	Better RFS and OS in OCD
Zhang, 2017 [24]	162	E1L3N	≥ 5% of TCs	Whole-tissue sections	N.S	PD-L1 ( +) on tumor cells =  > shorter CSS
Miyama, 2018 [25]	271	SP263	≥ 5% of TCs	TMA	Higher T stage and LVI	Shorter MFS and OS at high platelet count
Arriola, 2019 [26]	72	E1J2J	≥ 1% of TCs	Whole-tissue sections	Higher T stage, squamous differentiation	N.S
Present study	105	22C3	CPS ≥ 10	Whole-tissue sections	Higher T stage, LN invasion at diagnosis	Shorter CSS and OS

TCs tumor cells; CPS combined positive score; TMA tissue microarray; LVI lymphovascular invasion; N.S not significant; CSS cancer-specific survival; RFS recurrence-free survival; OS overall survival; MFS metastasis-free survival; OCD organ confined disease; LN lymph node